Login to Your Account



MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M

By Nuala Moran
BioWorld International Correspondent

Wednesday, December 7, 2011
In a potential $450 million deal, MacroGenics Inc. has signed up the privately held French pharmaceutical company Servier as partner for MGA271, a first-in-class antibody targeting B7-H3, an antigen that is expressed in a long and growing list of solid tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription